Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Eyenovia, Inc.
  6. News
  7. Summary
    EYEN   US30234E1047

EYENOVIA, INC.

(EYEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eyenovia : Arctic Vision Expand Licence Deal to Include Another Eye Drug

09/17/2021 | 03:52am EST


ę MT Newswires 2021
All news about EYENOVIA, INC.
12/03EYENOVIA, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhi..
AQ
11/17INSIDER BUY : Eyenovia
MT
11/12EYENOVIA, INC. Management's Discussion and Analysis of Financial Condition and Results..
AQ
11/10Eyenovia Reports Third Quarter 2021 Financial Results - Form 8-K
PU
11/10EYENOVIA, INC. : Results of Operations and Financial Condition, Change in Directors or Pri..
AQ
11/10Eyenovia, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sep..
CI
11/10Eyenovia, Inc. Announces Resignation of Fred Eshelman from Board
CI
11/10Eyenovia Reports Third Quarter 2021 Financial Results
GL
11/08Eyenovia to Participate in Myopia Panel Discussion at the Eyecelerator@AAO 2021 Meeting
GL
11/08Eyenovia to Participate in Myopia Panel Discussion at the Eyecelerator@AAO 2021 Meeting
GL
More news
Analyst Recommendations on EYENOVIA, INC.
More recommendations
Financials (USD)
Sales 2021 4,00 M - -
Net income 2021 -21,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,12x
Yield 2021 -
Capitalization 99,4 M 99,4 M -
Capi. / Sales 2021 24,8x
Capi. / Sales 2022 55,9x
Nbr of Employees 33
Free-Float 65,7%
Chart EYENOVIA, INC.
Duration : Period :
Eyenovia, Inc. Technical Analysis Chart | EYEN | US30234E1047 | MarketScreener
Technical analysis trends EYENOVIA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 3,50 $
Average target price 14,67 $
Spread / Average Target 319%
EPS Revisions
Managers and Directors
Sean Ianchulev President, CEO, Director & Chief Medical Officer
John P. Gandolfo Chief Financial Officer & Secretary
Fredric N. Eshelman Chairman
Luke Clauson VP-Engineering, Research & Development
Jennifer Clasby VP-Clinical Operations & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
EYENOVIA, INC.-42.24%99
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641